KR100862176B1 - 신규한 벤조일구아니딘 염 및 이를 포함하는 약제학적 조성물 - Google Patents

신규한 벤조일구아니딘 염 및 이를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR100862176B1
KR100862176B1 KR1020037010723A KR20037010723A KR100862176B1 KR 100862176 B1 KR100862176 B1 KR 100862176B1 KR 1020037010723 A KR1020037010723 A KR 1020037010723A KR 20037010723 A KR20037010723 A KR 20037010723A KR 100862176 B1 KR100862176 B1 KR 100862176B1
Authority
KR
South Korea
Prior art keywords
formula
compound
heart
ischemia
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037010723A
Other languages
English (en)
Korean (ko)
Other versions
KR20030075197A (ko
Inventor
아익마이에르크리스티안
지거페터
쾨르너볼크마르
헤르터롤프
랄베르너
Original Assignee
베링거 잉겔하임 파르마 게엠베하 운트 코 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 filed Critical 베링거 잉겔하임 파르마 게엠베하 운트 코 카게
Publication of KR20030075197A publication Critical patent/KR20030075197A/ko
Application granted granted Critical
Publication of KR100862176B1 publication Critical patent/KR100862176B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020037010723A 2001-02-15 2002-02-14 신규한 벤조일구아니딘 염 및 이를 포함하는 약제학적 조성물 Expired - Fee Related KR100862176B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10106970.7 2001-02-15
DE10106970A DE10106970A1 (de) 2001-02-15 2001-02-15 Neues Benzoylguanidinsalz
PCT/EP2002/001535 WO2002064563A1 (de) 2001-02-15 2002-02-14 Neues benzoylguanidinsalz

Publications (2)

Publication Number Publication Date
KR20030075197A KR20030075197A (ko) 2003-09-22
KR100862176B1 true KR100862176B1 (ko) 2008-10-09

Family

ID=7674094

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037010723A Expired - Fee Related KR100862176B1 (ko) 2001-02-15 2002-02-14 신규한 벤조일구아니딘 염 및 이를 포함하는 약제학적 조성물

Country Status (31)

Country Link
US (2) US20080025919A1 (enExample)
EP (1) EP1362030B1 (enExample)
JP (3) JP4408626B2 (enExample)
KR (1) KR100862176B1 (enExample)
CN (1) CN1222510C (enExample)
AT (1) ATE553078T1 (enExample)
AU (1) AU2002250939B2 (enExample)
BG (1) BG66330B1 (enExample)
BR (1) BR0207867A (enExample)
CA (1) CA2434829C (enExample)
CY (1) CY1112878T1 (enExample)
CZ (1) CZ303277B6 (enExample)
DE (1) DE10106970A1 (enExample)
DK (1) DK1362030T3 (enExample)
EA (1) EA006245B1 (enExample)
EC (1) ECSP034708A (enExample)
EE (1) EE200300393A (enExample)
ES (1) ES2385472T3 (enExample)
HR (1) HRP20030653B1 (enExample)
HU (1) HU230035B1 (enExample)
IL (1) IL156934A (enExample)
NO (1) NO20033299D0 (enExample)
NZ (1) NZ528081A (enExample)
PL (1) PL213300B1 (enExample)
PT (1) PT1362030E (enExample)
RS (1) RS52014B (enExample)
SI (1) SI1362030T1 (enExample)
SK (1) SK287830B6 (enExample)
UA (1) UA74625C2 (enExample)
WO (1) WO2002064563A1 (enExample)
ZA (1) ZA200305365B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
US20110118262A1 (en) * 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
US10405746B2 (en) * 2014-04-14 2019-09-10 The University Of Memphis Research Foundation Wireless analog passive sensors
US12369831B1 (en) 2018-04-30 2025-07-29 Bashir I. Morshed Apparatus and method to capture body signals with conjugate coils and paired coils

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017176A2 (de) * 1998-09-22 2000-03-30 Boehringer Ingelheim Pharma Kg Benzolylguanidin-abkömmlinge mit vorteilhaften eigenschaften, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von arzneimiteln

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
US6323207B1 (en) * 1998-09-22 2001-11-27 Boehringer Ingelheim Pharma Kg Benzoylguanidine derivatives
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017176A2 (de) * 1998-09-22 2000-03-30 Boehringer Ingelheim Pharma Kg Benzolylguanidin-abkömmlinge mit vorteilhaften eigenschaften, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von arzneimiteln

Also Published As

Publication number Publication date
PL362129A1 (en) 2004-10-18
HU230035B1 (hu) 2015-05-28
BG108065A (bg) 2005-01-31
IL156934A (en) 2005-12-18
SK10202003A3 (sk) 2004-02-03
ES2385472T3 (es) 2012-07-25
YU61503A (sh) 2006-05-25
HRP20030653B1 (en) 2012-06-30
HRP20030653A2 (en) 2005-06-30
JP2009235097A (ja) 2009-10-15
EA006245B1 (ru) 2005-10-27
KR20030075197A (ko) 2003-09-22
CA2434829A1 (en) 2002-08-22
DK1362030T3 (da) 2012-07-09
JP4408626B2 (ja) 2010-02-03
PT1362030E (pt) 2012-07-04
AU2002250939B2 (en) 2007-09-06
EP1362030A1 (de) 2003-11-19
EA200300771A1 (ru) 2004-02-26
CN1491213A (zh) 2004-04-21
HUP0303027A2 (hu) 2003-12-29
BR0207867A (pt) 2004-03-23
NZ528081A (en) 2005-10-28
NO20033299L (no) 2003-07-22
JP5745215B2 (ja) 2015-07-08
PL213300B1 (pl) 2013-02-28
RS52014B (sr) 2012-04-30
SI1362030T1 (sl) 2012-07-31
SK287830B6 (sk) 2011-11-04
CY1112878T1 (el) 2016-04-13
CN1222510C (zh) 2005-10-12
BG66330B1 (bg) 2013-06-28
EE200300393A (et) 2003-12-15
US20080025919A1 (en) 2008-01-31
IL156934A0 (en) 2004-02-08
DE10106970A1 (de) 2002-08-29
CA2434829C (en) 2009-12-08
ATE553078T1 (de) 2012-04-15
CZ20032210A3 (cs) 2003-12-17
JP2013107906A (ja) 2013-06-06
US20080241077A1 (en) 2008-10-02
JP2004518721A (ja) 2004-06-24
HK1064093A1 (zh) 2005-01-21
NO20033299D0 (no) 2003-07-22
WO2002064563A1 (de) 2002-08-22
UA74625C2 (en) 2006-01-16
ZA200305365B (en) 2004-04-22
ECSP034708A (es) 2003-12-24
EP1362030B1 (de) 2012-04-11
HUP0303027A3 (en) 2010-04-28
CZ303277B6 (cs) 2012-07-11

Similar Documents

Publication Publication Date Title
JP5745215B2 (ja) 新規ベンゾイルグアニジン塩
US10875849B2 (en) Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
WO2016000568A1 (zh) 一种治疗痛风的化合物
WO2016145622A1 (zh) 苯并咪唑衍生物及其制备方法和医药用途
JP3853389B2 (ja) 新規の３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１］ノナン−化合物、その製法及び抗不整脈剤
US6730678B2 (en) Benzoylguanidine salt and hydrates thereof
HK1064093B (en) Benzoylguanidine salt
KR20070087606A (ko) 인자 ｘａ 억제제의 결정질 형태
MXPA03007192A (en) Novel benzoylguanidine salt
WO2024169765A1 (zh) 一种二肽类化合物的盐、其制备方法和用途
CN118496301A (zh) 一种二肽类化合物的盐、其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130923

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20140919

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20150918

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20161002

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20161002